Business Description
Fortress Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US34960Q2084
Total Employee Number:
78Description
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.77 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.33 | |||||
Debt-to-EBITDA | 0.37 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 0.04 | |||||
Beneish M-Score | -5.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -43.8 | |||||
3-Year EBITDA Growth Rate | 71.9 | |||||
3-Year EPS without NRI Growth Rate | 41.1 | |||||
3-Year FCF Growth Rate | 57.5 | |||||
3-Year Book Growth Rate | -34.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.58 | |||||
9-Day RSI | 54.85 | |||||
14-Day RSI | 62.05 | |||||
3-1 Month Momentum % | 35.31 | |||||
6-1 Month Momentum % | 94.25 | |||||
12-1 Month Momentum % | 133.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.86 | |||||
Quick Ratio | 2.77 | |||||
Cash Ratio | 2.47 | |||||
Days Inventory | 183.16 | |||||
Days Sales Outstanding | 117.43 | |||||
Days Payable | 310.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -62.1 | |||||
Shareholder Yield % | -19.27 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 66.22 | |||||
Operating Margin % | -84.36 | |||||
Net Margin % | 193.12 | |||||
EBITDA Margin % | 220.57 | |||||
ROE % | 191.21 | |||||
ROA % | 60.17 | |||||
ROIC % | -82.21 | |||||
3-Year ROIIC % | -434.92 | |||||
ROC (Joel Greenblatt) % | 933.9 | |||||
ROCE % | 97.63 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.87 | |||||
Price-to-Owner-Earnings | 0.67 | |||||
PS Ratio | 1.35 | |||||
PB Ratio | 0.56 | |||||
Price-to-Free-Cash-Flow | 0.72 | |||||
Price-to-Operating-Cash-Flow | 0.72 | |||||
EV-to-EBIT | -0.5 | |||||
EV-to-EBITDA | -0.49 | |||||
EV-to-Revenue | -1.07 | |||||
EV-to-FCF | -0.45 | |||||
Earnings Yield (Greenblatt) % | -200 | |||||
FCF Yield % | 173.19 |
GF Valueâ„¢
Fortress Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fortress Biotech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 138 days | ||
| General meeting for 2026 | 2026-06-17 10:00 | 20.25 (-3.57%) | ||
| A.G.P.’s Annual Virtual Healthcare Conference | 2026-05-20 17:00 | 16.09 (-0.62%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 16:30 | 13.34 (-1.77%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 13.34 (-1.77%) | ||
| H.C. Wainwright 2nd Annual Royalty Company Virtual Conference | 2026-05-06 12:30 | 14.27 (+1.35%) | ||
| Annual report for 2025 | 2026-03-31 | 13.27 (-0.60%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 13.26 (+0.30%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 6.53 (-4.67%) | ||
| Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference | 2025-09-11 | 9.04 (+0.96%) |
Show
Entries
Guru Commentaries on NAS:FBIOP.PFD
No articles.
Press Release
Articles on Fortress Biotech Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers